1,719 results on '"Capper, David"'
Search Results
102. Data from Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
103. Data from Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations
104. Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
105. Supplementary Table from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
106. Supplementary Table S4 from Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
107. Supplementary Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
108. Data from Targeting the BRAF V600E Mutation in Multiple Myeloma
109. Table S1 from Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations
110. Supplementary Table S3 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
111. Data from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
112. Supplementary Data from Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
113. Supplementary Figure from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
114. Supplementary Table 1 from Targeting the BRAF V600E Mutation in Multiple Myeloma
115. Table S4 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
116. Supplemental Table Legend from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
117. Figure S1, Figure S2, Figure S3, Figure S4 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
118. Supplementary Table 1, Figures 1 - 3 from Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma
119. Adult intracranial ependymoma - relevance of DNA methylation profiling for diagnosis, prognosis and treatment
120. The Heir-Locator's Lost Inheritance
121. Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerability
122. Diffuse hemispheric glioma, H3 G34-mutant
123. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline
124. Original Research Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry
125. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
126. Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study
127. Consideration in the modification of contracts
128. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities
129. Correction to: DNA methylation signature is prognostic of choroid plexus tumor aggressiveness
130. YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis
131. DNA methylation signature is prognostic of choroid plexus tumor aggressiveness
132. New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X
133. Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre
134. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
135. Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directions
136. Celebrating the 50th Anniversary of the MacDermott Lecture Series at Queen’s University Belfast
137. Methylation differences in Alzheimer’s disease neuropathologic change in the aged human brain
138. Robust methylation‐based classification of brain tumours using nanopore sequencing
139. BIOM-32. DNA METHYLATION SUBCLASSES PREDICT THE BENEFIT FROM GROSS TOTAL TUMOR RESECTION IN IDH-WILDTYPE GLIOBLASTOMA PATIENTS
140. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers
141. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
142. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway
143. Litigation Funding in Ireland
144. SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature
145. No Tort Liability for Breaching Freezing Orders
146. Spinal metastasis of gliosarcoma: Array-based comparative genomic hybridization for confirmation of metastatic spread
147. Diffuse Astrocytomas: Immunohistochemistry of MGMT Expression
148. Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1
149. Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions
150. Anaplastic ganglioglioma—A diagnosis comprising several distinct tumour types
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.